Modern pharmacotherapy for erectile dysfunction: Evolving concepts with central and peripheral acting agents

Current Opinion in Urology

Volumn 11, Issue 6, 2001, Pages 625-630

  Brock, Gerald B ^a   Bochinski, Derek ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 AMINOPHENYL) 1,2 DIHYDRO 1 OXO 7 (2 PYRIDINYLMETHOXY) 4 (3,4,5 TRIMETHOXYPHENYL) 3 ISOQUINOLINECARBOXYLIC ACID METHYL ESTER; ALPHA MELANOTROPIN[4-10]; APOMORPHINE; COMPOUND 14; IMIDAZOQUINAZOLINONE DERIVATIVE; INTERMEDIN DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; QUINAZOLINONE DERIVATIVE; SILDENAFIL; TADALAFIL; TARDALAFIL; TARDENAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

ANIMAL EXPERIMENT; CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; ERECTILE DYSFUNCTION; HEADACHE; HUMAN; MALE; META ANALYSIS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYNCOPE; TREATMENT OUTCOME;

HUMANS; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS;

EID: 0034762369     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200111000-00011     Document Type: Review

References (40)

1. The world-wide prevalence and epidemiology of erectile dysfunction
2. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study
3. Incidence of erectile dysfunction in men 40 to 69 years old: Longitudinal results from the Massachusetts Male Aging Study
4. Erectile dysfunction in general medicine practice: Prevalence and clinical correlates
5. Impotence
6. Hypertension is associated with severe erectile dysfunction
7. Prevalence and risk factors of sexual dysfunction in men and women
8. Erectile dysfunction
9. Cyclic nucleotide phosphodiesterases: Relating structure and function
10. Expression of different phosphodiesterase genes in human cavernous smooth muscle
11. Oral sildenafil in the treatment of erectile dysfunction
12. Switching from intracavernous prostaglandin E1 injections to oral sildenafil citrate in patients with erectile dysfunction: Results of a multicenter European study
13. Effects of sildenafil citrate (Viagra) combined with nitrate on the heart
14. Use of sildenafil (Viagra) in patients with cardiovascular disease
15. Hemodynamic effects of sildenafil in men with severe coronary artery disease
16. Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication
17. Long-term efficacy and safety of oral Viagra (sildenafil citrate) in men with erectile dysfunction and the effect of randomized treatment withdrawal
18. Sildenafil improves nocturnal penile erections in organic impotence
19. Sildenafil taken at bedtime significantly increases nocturnal erections: Results of a placebo-controlled study
20. Effect of sildenafil citrate on post-radical prostatectomy erectile dysfunction
21. Clinical efficacy of sildenafil in patients on chronic dialysis
22. Sildenafil versus intracavernous injection therapy: Efficacy and preference in patients on intracavernous injection for more than 1 year
23. A new method for the evaluation of erectile dysfunction: Sildenafil plus Doppler ultrasonography
24. Initial results utilizing combination therapy for patients with a suboptimal response to either alprostadil or sildenafil monotherapy
25. Results from different patient populations using combined therapy with alprostadil and sildenafil: Predictors of satisfaction
26. Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction
27. On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction
28. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients and pharmacokinetic study
29. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: The first at-home clinical trial
30. N-3-substituted imidazoquinazolinones: Potent and selective PDE5 inhibitors as potential agents for the treatment of erectile dysfunction
31. Potentiation of penile tumescence by T-1032, a new potent and specific phosphodiesterase type V inhibitor in dogs
32. Apomorphine: An update of clinical trial resuls
33. Central noradrenergic control of penile erection
34. Efficacy and safety of fixed-dose and dose optimization regimes of sublingual apomorphine versus placebo in men with erectile dysfunction
35. Effect of an alpha-melanocyte stimulating hormone analogue on penile erection and sexual desire in men with organic erectile dysfunction
36. Melanocortin receptor agonists, penile erection and sexual motivation: Human studies with melanotan II
37. Potential application of gene therapy for the treatment of erectile dysfunction
38. Novel pharmacological approaches in the treatment of erectile dysfunction